+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Von Hippel-Lindau disease (VHL) is a genetic condition that increases the risk of tumors and cysts developing in several organs. These can include hemangioblastomas in the brain, spinal cord, or retina, kidney cancer, and tumors of the adrenal glands...

Search Bar & Filters

Found 14 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the diagnostic value of a new protein-specific probe called 18F-T2 in PETCT imaging for people with solid tumors that are likely to express high levels of CAIX protein. The study will also assess how safe and tolerable the 18F-T2 injection is, as well as measure its radiation dosage. This research is important to better understand how well 18F-T2 can detect these tumors compared to standard imaging techniques. Participants with tumors suspected to express high levels of CAIX will receive an intravenous injection of 18F-T2. About an hour after the injection, PETCT imaging will be performed to capture detailed images of the tumors. Within one week, participants will also undergo a whole-body PETCT scan using 18F-FDG, a commonly used imaging agent, to allow comparison between the two imaging methods. During the study, participants will be monitored for any adverse events within 24 hours after the 18F-T2 injection to evaluate safety and tolerability. Researchers will measure the diagnostic sensitivity and specificity of 18F-T2 PETCT for detecting CAIX-positive tumors. They will also assess uptake values in tumors on both 18F-T2 and 18F-FDG scans, analyze the correlation between 18F-T2 uptake and CAIX expression in tissue samples, and evaluate radiation dosimetry. The study will continue until one month after completion for outcome assessments.

Age: 18Years +All GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are studying the use of 68Ga-DOTATATE PETMRI imaging to improve diagnosis and management of patients with somatostatin receptor-positive central nervous system tumors. This includes meningiomas and other brain tumors such as esthesioneuroblastoma, hemangioblastoma, medulloblastoma, paraganglioma, pituitary adenoma, and certain metastatic tumors. The study aims to determine if this imaging method better distinguishes tumor recurrence from post-treatment changes and assesses residual tumor extent, especially in challenging cases like high-grade tumors or post-radiation changes. Participants undergo a specialized hybrid Gallium-68-DOTATATE PETMRI scan instead of or alongside their standard MRI exams. This scan is performed prior to surgery for meningioma patients and may be repeated up to two times as part of standard care follow-up. For patients with other somatostatin receptor-positive CNS tumors, the PETMRI is performed during their regular MRI evaluations. In some cases where a 3 Tesla MRI is not possible, a 1.5 Tesla MRI combined with PETCT fusion imaging is used. During the study, participants have imaging sessions to assess tumor presence and changes over time, with data collected for up to 10 years. Researchers evaluate the diagnostic value of the PETMRI scans and correlate findings with tumor tissue markers such as SSTR2 expression, Ki67, progesterone receptor, and EGFR. The study is ongoing with long-term follow-up to monitor the imagings clinical benefit and support treatment decisions.

Age: 18Years - 100YearsAll GendersPhase 4
1 location
P

Actively Recruiting

Researchers are studying belzutifan monotherapy to assess its effectiveness and safety in treating advanced pheochromocytomaparaganglioma PPGL, pancreatic neuroendocrine tumors pNET, von Hippel-Lindau VHL disease-associated tumors, advanced wild-type gastrointestinal stromal tumor wt GIST, and other advanced solid tumors with Hypoxia Inducible Factor-2 alpha HIF-2 genetic alterations. The primary goal is to measure the objective response rate ORR using standardized criteria through independent review. Participants will receive belzutifan orally at a dose of 120 mg once daily. This treatment continues until the disease progresses or the participant decides to stop. The study is designed as a single-group phase 2 trial focusing solely on belzutifan monotherapy without a comparison group. During the study, participants will be regularly monitored for treatment response, duration and time to response, disease control, progression-free survival, overall survival, and any adverse events. These assessments will be conducted for up to approximately 5.5 years. Safety and efficacy are closely observed throughout this period to understand the treatment impact over time.

Age: 12Years +All GendersPhase 2
84 locations
O

Actively Recruiting

This observational study focuses on patients with Von Hippel Lindau vHL disease. It aims to collect detailed information about the disease status, including lesion development, surgical history, and systemic therapy use. Researchers seek to understand how different VHL gene mutations relate to patterns of lesion development and responses to the drug belzutifan in specific organs. The study also gathers quality of life data from affected individuals. Participants will not receive any study treatments, as this is a data collection protocol. Information will be gathered both retrospectively and prospectively regarding surgeries, therapies, and lesion progression. The study will observe patients over an average period of one year to assess progression-free survival. Quality of life assessments will also be part of the data collected. During the study, participants will provide medical history and undergo evaluations to document disease progression and treatment responses. Data collected will include clinical status, treatment history, and patient-reported quality of life. The study is sponsored by M.D. Anderson Cancer Center and will continue until December 2026. Participants involvement includes sharing information that helps researchers understand vHL disease better and monitor changes over time.

Age: 18Years +All Genders
1 location
L

Actively Recruiting

Researchers are investigating new treatments for advanced solid tumors and von Hippel-Lindau VHL-related tumors, which include cancers that have spread or cannot be removed by surgery and tumors caused by a genetic condition called VHL disease. This extension trial focuses on a drug called belzutifan MK-6482, which is designed to block a protein that helps tumors grow. The study aims to learn about the long-term effects of belzutifan and how long participants live after starting treatment. Participants who were already receiving belzutifan alone, belzutifan combined with other therapies, or non-belzutifan therapies in previous related studies can join this extension. They will continue their current treatment dose and schedule without changes. Treatment will continue until the disease progresses, unacceptable side effects occur, consent is withdrawn, death, investigator decision, or the study ends. During the study, participants will continue taking their assigned treatments and be monitored regularly. Researchers will track overall survival for up to approximately seven years and observe any adverse events or reasons for stopping treatment for up to two years. The study will also assess safety and treatment effects over time, lasting until April 2034.

Age: 18Years +All GendersPhase 3
57 locations
S

Actively Recruiting

Researchers are studying familial cancer in children and their families to discover new genetic causes. This observational study focuses on families with a history of cancer to identify novel cancer-predisposing genes and genetic variants. The study aims to expand understanding of hereditary cancer predisposition by using next generation sequencing NGS technologies and establishing a linked data registry and biological sample repository. Participants provide blood samples, saliva, skin samples when needed, and occasionally leftover tumor or bone marrow samples. These biological specimens are stored in a biorepository and analyzed to detect gene changes potentially responsible for familial cancer. Participants may also be asked yearly for updated health and family history information if they agree to future contact. During the study, researchers collect medical and family histories along with biological samples to perform DNA sequencing and other genetic analyses. Samples are coded to protect identity and stored for current and future research. The primary outcome is identifying new cancer-related genes over up to 20 years. Participation involves sample collection and periodic updates, with ongoing confidentiality and long-term monitoring.

All AgesAll Genders
1 location
S

Actively Recruiting

Healthy Volunteer

Neuroendocrine neoplasms NENs are a diverse group of tumors that arise from hormone-producing cells and can develop in various organs. Their behavior ranges from benign to aggressive, sometimes causing serious health problems due to excess hormone production. Many NENs are inherited or part of genetic syndromes, while others arise from non-inherited genetic changes. This research aims to identify genetic defects causing NENs in a large group of Mexican patients, improving understanding of their molecular causes and potential treatment targets. This study collects blood and tissue samples from adult patients with different types of NENs at two hospitals in Mexico City. Participants undergo genetic testing using three methods targeted gene sequencing, analysis of gene copy number changes, and full exome sequencing in selected cases. The study also gathers detailed clinical, laboratory, imaging, and pathology information, and offers genetic screening to family members when appropriate. Samples and data are carefully stored and analyzed to detect genetic variants associated with NENs. Participants provide blood and, when possible, tumor tissue samples for DNA analysis. Researchers collect clinical and family history data, along with laboratory and imaging results. The main outcome is identifying genetic defects linked to NENs over a follow-up period of up to 15 years. Participants who want to know their genetic results receive detailed reports. The study seeks to correlate genetic findings with clinical features and outcomes, aiming to discover new genetic associations and improve future diagnosis and treatment strategies.

Age: 18Years +All Genders
3 locations
H

Actively Recruiting

Researchers are conducting an observational study to create a comprehensive registry system that collects data on various rare diseases RD. The goal is to group different rare diseases together to better understand their clinical features, diagnosis, treatments, and patient outcomes. This registry aims to support research by improving knowledge about risk factors, disease progression, and resource use related to rare diseases. The study focuses on gathering data from patients with clinical or molecular diagnoses of specific rare diseases such as Amyloidosis, Sarcoidosis, Phacomatosis, and many others. Data is collected systematically from electronic medical records and patient reports to describe disease occurrence, diagnosis patterns, treatment modalities, and responses. The registry also plans to develop an alert system to identify possible rare disease cases from medical records. Participants are observed over time with data collected on survival rates, mortality, treatment timelines, clinical characteristics, and adverse events related to treatment. Researchers assess outcomes up to five years after enrollment, including time to first treatment and treatment responses. Patient-reported outcomes and demographic profiles are also recorded to understand the impact of rare diseases. The study spans multiple years, aiming to enhance disease knowledge and support future research and patient care improvements.

All AgesAll Genders
1 location
S

Actively Recruiting

This research aims to understand somatic mutations in normal kidney cells of patients with Von Hippel Lindau VHL disease, a genetic condition that increases the risk of kidney cancer. The study compares mutation rates in kidney cells from VHL patients to those from individuals without the disease, seeking to discover if mutations accumulate more in VHL patients and what factors influence these changes. Participants will provide one blood sample and multiple urine samples annually for 3 to 5 years. The urine samples are used to isolate kidney tubule cells, which are then cultured and analyzed genetically. If participants undergo kidney tumor surgery, tissue samples from the tumor and nearby normal kidney will also be collected for genetic testing. The study includes two groups VHL patients and control individuals without the disease. During the study, researchers will monitor mutation rates in kidney cells collected from urine over about three years, with a minimum of 3 months and up to 3 years of observation. They will also quantify pre-cancer cells in these samples. Sample collection aligns with patients yearly hospital screenings. The study aims to better understand mutation patterns that may lead to tumor development in VHL disease.

Age: 18Years +All Genders
1 location
M

Actively Recruiting

Healthy Volunteer

Researchers are collecting detailed information from patients with Von Hippel-Lindau Disease VHL and related genetic conditions such as Birt-Hogg-Dube Syndrome, Hereditary Leiomyomatosis and Renal Cell Cancer, and SDHB Gene Mutation. This observational study aims to build a large database called MyVHL to understand how lifestyle, medications, and other factors affect these rare conditions and the quality of life of those affected. Due to the rarity of these diseases, this study helps identify patterns that may influence tumor growth or disease progression. Participants contribute data about their health, including information on tumors in various organs such as the central nervous system, kidneys, adrenal glands, retina, thyroid, ears, pancreas, lungs, liver, and skin. The study collects information on the number and size of these tumors as related to specific genetic mutations. This data gathering continues on average for about one year through the studys completion. During the study, participants provide ongoing health information which researchers use to track tumor development and other disease-related changes. This helps researchers gain insights into disease patterns and potential risk factors. The study includes all patients with VHL and related conditions, and participation involves sharing health data over time. The study is observational and does not include treatments, focusing instead on understanding the natural history of these rare diseases.

All AgesAll Genders
1 location

1-10 of 14

1